公开(公告)号：US20140234344A1

公开(公告)日：2014-08-21

申请号：US14165400

申请日：2014-01-27

Applicant: Baylor Research Institute

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  A61K39/00 ,  A61K2039/6056 ,  C07K14/005 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/74 ,  C07K2317/80 ,  C07K2319/00 ,  C12N2740/16222 ,  C12N2740/16322

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Abstract translation: 本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。 在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗-CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。

公开(公告)号：US12016915B2

公开(公告)日：2024-06-25

申请号：US17454108

申请日：2021-11-09

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon Oh ,  Dapeng Li ,  Jacques Banchereau ,  Gerard Zurawski ,  Sandra Zurawski

IPC: A61K39/145 ,  A61K39/00 ,  A61K47/68 ,  A61K51/10 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C12N5/0784 ,  C12N7/00

CPC classification number: A61K39/145 ,  A61K47/6849 ,  A61K51/1027 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C12N5/0639 ,  C12N7/00 ,  A61K2039/5154 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

公开(公告)号：US11806390B2

公开(公告)日：2023-11-07

申请号：US17301704

申请日：2021-04-12

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Gerard Zurawski ,  Jacques F. Banchereau ,  Anne-Laure Flamar ,  Peter Klucar ,  Keiko Akagawa ,  Sandra Zurawski ,  SangKon Oh

IPC: A61K39/00 ,  A61K39/385 ,  C07K14/005 ,  C07K16/00 ,  G01N33/68 ,  C07K16/28 ,  C07K14/435

CPC classification number: A61K39/001129 ,  A61K39/385 ,  C07K14/005 ,  C07K14/435 ,  C07K16/00 ,  C07K16/2878 ,  G01N33/6863 ,  A61K39/00 ,  A61K2039/6056 ,  A61K2039/627 ,  A61K2039/64 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/77 ,  C07K2317/80 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2740/16222 ,  C12N2740/16322 ,  C12N2760/16122 ,  C12N2770/24222 ,  C12N2770/24234 ,  Y02A50/30

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US10940195B2

公开(公告)日：2021-03-09

申请号：US16397214

申请日：2019-04-29

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon Oh ,  Sandra Zurawski ,  Gerard Zurawski

IPC: A61K39/12 ,  A61K39/395 ,  C07K14/025 ,  C07K16/00 ,  C07K16/28 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US10683361B2

公开(公告)日：2020-06-16

申请号：US16143995

申请日：2018-09-27

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: A61K39/395 ,  C07K16/28 ,  C07K14/005 ,  A61K39/00

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US10570208B2

公开(公告)日：2020-02-25

申请号：US16210188

申请日：2018-12-05

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Yong-Jun Liu ,  Sandra Zurawski ,  SangKon Oh ,  Shino Hanabuchi ,  Haruyuki Fujita ,  Hideki Ueno ,  Patrick Blanco ,  Hyemee Joo

IPC: C07H21/04 ,  C12P21/06 ,  C12N5/00 ,  C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  A61K39/00

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

公开(公告)号：US20190092869A1

公开(公告)日：2019-03-28

申请号：US16210188

申请日：2018-12-05

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Yong-Jun Liu ,  Sandra Zurawski ,  SangKon Oh ,  Shino Hanabuchi ,  Haruyuki Fujita ,  Hideki Ueno ,  Patrick Blanco ,  Hyemee Joo

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

公开(公告)号：US20190085088A1

公开(公告)日：2019-03-21

申请号：US16143995

申请日：2018-09-27

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005 ,  A61K39/00

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US10087256B2

公开(公告)日：2018-10-02

申请号：US15401856

申请日：2017-01-09

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005 ,  A61K39/00

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US09315580B2

公开(公告)日：2016-04-19

申请号：US13863131

申请日：2013-04-15

Applicant: Baylor Research Institute

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  Eynav Klechevsky ,  SangKon Oh

IPC: C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  A61K39/00 ,  A61K39/145 ,  A61K39/21 ,  C07K14/47 ,  C12N7/00 ,  C07K14/005 ,  A61K39/12

CPC classification number: C07K16/2896 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/55561 ,  A61K2039/6056 ,  C07K14/005 ,  C07K14/4748 ,  C07K16/2851 ,  C07K2319/00 ,  C07K2319/33 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2760/16134

Abstract: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.

Abstract translation: 本发明包括分离的抗兰格林疫苗，分离的抗 - 兰格林抗体的羧基末端制备和使用分离的抗 - 兰格林抗体或其结合片段和一种或多种抗原肽的方法，其中当两种或多种抗原 存在肽，肽被包含至少一个糖基化位点的一个或多个接头肽隔开。 本发明还包括用于表达抗Langerin抗原递送载体的分离载体及其制备和用途。